TriangleHEALTH PROFESSIONAL · SOURCE READING
ATA pediatric high risk
Source: Childhood Thyroid Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: April 3, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Initial postoperative staging includes a TSH-stimulated thyroglobulin and diagnostic 123I whole-body scan for further stratification and determination with 131I.
TSH suppression should be targeted to serum levels of less than 0.1 mIU/L.
In patients with no evidence of disease, surveillance should include ultrasonography at 6 months postoperatively and then every 6 to 12 months for 5 years (and then less frequently), as well as thyroglobulin levels (on hormone replacement therapy) every 3 to 6 months for 3 years and then annually.
TSH-stimulated thyroglobulin and, possibly, a diagnostic 123I scan in 1 to 2 years in patients treated with 131I.
For patients with antithyroglobulin antibodies, deferred postoperative staging to allow time for antibody clearance, except in patients with T4 or M1 disease.
Preserved source evidence · Not medical advice